Argitalpenak (55) Felipe Villacampa Aubá argitalpenak

2024

  1. Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?

    Translational Andrology and Urology

  2. First-line Management of Metastatic Urothelial Cancer: Current and Future Perspectives After the EV-302 and CheckMate-901 Studies

    Clinical Genitourinary Cancer

2023

  1. Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years

    The Journal of urology, Vol. 209, Núm. 1, pp. 261-270

  2. Reply by Authors

    The Journal of urology, Vol. 209, Núm. 1, pp. 270

2022

  1. BlaDimiR: A Urine-based miRNA Score for Accurate Bladder Cancer Diagnosis and Follow-up

    European Urology

  2. Comparison of surgical approaches to radical prostatectomy in our series beyond oncological and functional outcomes

    Actas Urologicas Espanolas, Vol. 46, Núm. 5, pp. 275-284

  3. Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study

    European Urology Open Science, Vol. 40, pp. 38-45

  4. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial

    World Journal of Urology, Vol. 40, Núm. 4, pp. 999-1004

2021

  1. Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia

    Urologic Oncology: Seminars and Original Investigations, Vol. 39, Núm. 1, pp. 76.e9-76.e14

  2. What is the impact of post-radical prostatectomy urinary incontinence on everyday quality of life? Linking Pad usage and International Consultation on Incontinence Questionnaire Short-Form (ICIQ-SF) for a COMBined definition (PICOMB definition)

    Neurourology and Urodynamics, Vol. 40, Núm. 3, pp. 840-847

2020

  1. Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression

    Journal of Urology

  2. Recomendaciones de manejo de la afectación renal en el complejo esclerosis tuberosa

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 40, Núm. 2, pp. 142-151

  3. miRNA profiling in renal carcinoma suggest the existence of a group of pro-angionenic tumors in localized clear cell renal carcinoma

    PloS one, Vol. 15, Núm. 2, pp. e0229075

2019

  1. CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status

    Clinical Cancer Research, Vol. 25, Núm. 1, pp. 390-402

  2. Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status

    Scientific Reports, Vol. 9, Núm. 1

  3. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

    Nature Medicine

  4. Surgical thromboprophylaxis in daily urologic surgery: Beyond bridge therapy

    Actas Urologicas Espanolas, Vol. 43, Núm. 9, pp. 455-466

2018

  1. Mitomycin C HIVEC. Update and results in high risk patients

    Archivos Espanoles de Urologia, Vol. 71, Núm. 4, pp. 417-425

  2. Papel de la quimioterapia en el tratamiento del cáncer de próstata metastásico hormonosensible

    Archivos Espanoles de Urologia, Vol. 71, Núm. 3, pp. 276-280

  3. Programa formativo en cirugía endoscópica. Perspectivas de futuro

    Archivos Espanoles de Urologia, Vol. 71, Núm. 1, pp. 89-96